TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27802417
Drug: Sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium nitrite (0.3 mg kg ‐1) after placebo
Study: 27802417
Drug: Sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium nitrite (0.3 mg kg ‐1) after esomeprazole (3×40 mg)
Study: 26017285
Drug: Pulsatile double-compression-coated
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile double-compression-coated tablets
Study: 26017285
Drug: Core mini-tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core mini-tablets
Study: 21186984
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy + kefir (n=46)
Study: 21186984
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy + placebo (n=36)
Study: 21186984
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy + kefir
Study: 21186984
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy + placebo
Study: 18679637
Drug: Topical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical preparation containing urea, vitamins, and ceramides for 2 weeks
Study: 18679637
Drug: Topical urea-only
Normalized name: urea Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical urea-only preparation
Study: 14572570
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (CBT, Relaxation, Routine Care)
Study: 6833677
Drug: Inhaled verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled verapamil
Study: 6833677
Drug: Inhaled verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled verapamil (before a single inhalation test)
Study: 29576857
Drug: Naringenin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naringenin (20 mg daily)
Study: 29576857
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mg daily)
Study: 27088545
Drug: Systematic antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic antimicrobial therapy for all episodes of AB occurring ≤24 months after transplantation (53 patients)
Study: 27088545
Drug: No antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antimicrobial therapy (59 patients)
Study: 27088545
Drug: Systematic antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic antimicrobial therapy for AB (26 patients, per-protocol)
Study: 27088545
Drug: No antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antimicrobial therapy (50 patients, per-protocol)
Study: 27088545
Drug: Systematic screening
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic screening and treatment of AB
Study: 21463799
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid supplement (24 g of an oral supplement containing a leucine metabolite, glutamine, and arginine twice daily)
Study: 21463799
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no amino acid supplement)
Study: 9068344
Drug: Mivacurium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.6 mg
Study: 8453193
Drug: Calcium 600
Normalized name: Calcium 600
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium 600 mg/day
Study: 8453193
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus etidronate sodium 400 mg/day for 14 days every 3 months
Study: 8453193
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus etidronate plus phosphate (1 g twice daily for 3 days before etidronate)
Study: 3458431
Drug: Epirubicin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin Regimen A (40‐60 mg/m2 every three weeks)
Study: 3458431
Drug: Epirubicin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin Regimen B (20‐30 mg/m2/day for 3 days every three weeks)
Study: 31091608
Drug: Two-dose Hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose Hepatitis B vaccine (HepB) administered on a 0-6 month schedule
Study: 31091608
Drug: Three-dose Hepatitis
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose Hepatitis B vaccine (HepB) administered on a 0-1-6 month schedule
Study: 31091608
Drug: Challenge dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Challenge dose of Hepatitis B vaccine (HepB)
Study: 31091608
Drug: Participants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with anti-HBs titer <4, 4-6, and 7-9 mIU/ml at follow-up
Study: 23065023
Drug: Active compound
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active compound (200 μg selenium, 30 mg zinc, 2 mg vitamin A, 180 mg vitamin C, 30 mg vitamin E)
Study: 23065023
Drug: Active compound
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active compound
Study: 18723240
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT screening annually for 4 years
Study: 9408114
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) treatment (0.4 g/kg for five consecutive days)
Study: 9408114
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) maintenance treatment (0.4 g/kg weekly)
Study: 31019117
Drug: Anterior subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior subcutaneous transposition of the ulnar nerve
Study: 27769562
Drug: 10-day bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day bismuth quadruple therapy (bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day)
Study: 27769562
Drug: 10-day concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day concomitant therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily)
Study: 27769562
Drug: 14-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day triple therapy (lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg, all given twice daily)
Study: 20942614
Drug: Two tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of ibuprofen 200 mg/paracetamol 500 mg
Study: 20942614
Drug: One tablet
Normalized name: Hydone Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of ibuprofen 200 mg/paracetamol 500 mg
Study: 19032172
Drug: Tincture of
Normalized name: Tincture of opium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tincture of Opium (TOP) 6.66 mg morphine equivalents, twice daily
Study: 19032172
Drug: Tincture of
Normalized name: Tincture of opium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tincture of Opium (TOP) 13.3 mg morphine equivalents, twice daily
Study: 19032172
Drug: Tincture of
Normalized name: Tincture of opium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tincture of Opium (TOP) 20 mg morphine equivalents, twice daily
Study: 19032172
Drug: Tincture of
Normalized name: Tincture of opium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tincture of Opium (TOP) (all doses)
Study: 11062193
Drug: Telithromycin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telithromycin (800 mg perorally once daily for 10 days)
Study: 11062193
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg bid for 10 days)
Study: 8436153
Drug: Indomethacin 75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 75 mg and Captopril 25 mg (combined treatment)
Study: 3717319
Drug: Contralateral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contralateral therapy to the normal extremity
Study: 24772594
Drug: G-suit
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-suit
Study: 24772594
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no G-suit)
Study: 23321187
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg tolterodine, orally, twice daily
Study: 20860068
Drug: Venlafaxine (50-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (50-75 mg/day depending on weight)
Study: 15957511
Drug: Pulsed magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsed magnetic field therapy (PMFT)
Study: 12500022
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate (200 mg once daily) in type IIa dyslipidemia
Study: 12500022
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg once daily) in type IIa dyslipidemia
Study: 12500022
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate (200 mg once daily) in type IIb dyslipidemia
Study: 12500022
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg once daily) in type IIb dyslipidemia
Study: 10231206
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole (OM) 500 mg for adults, 7‐10 mg/kg for children, administered 2‐3 hours before operation and continued postoperatively every 8 hours for three doses if mild to severely inflamed; for complicated appendicitis, the same dose for 3 to 6 days depending on pus presence.
Study: 10231206
Drug: Ceftizoxime administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime administered 2 to 3 hours before operation and postoperatively every 6 hours for three doses if mild to severely inflamed; complicated cases received penicillin, chloramphenicol, and gentamicin for 3 to 6 days depending on pus presence.
Study: 8744845
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of carteolol 2% and pilocarpine 2% (CBS 341 A) eye-drops
Study: 31865938
Drug: FPG ≥4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG ≥4.5 mmol/L
Study: 24372613
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of l-theanine
Study: 24372613
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of l-theanine
Study: 24372613
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of l-theanine
Study: 22158729
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (0.5 g protein · kg BW(‐1) · d(‐1))
Study: 22158729
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (2.0 g protein · kg BW(‐1) · d(‐1))
Study: 18339272
Drug: Oral metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoprolol treatment
Study: 18339272
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration salt treatment
Study: 16355944
Drug: ketamine, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine, 0.5 mg/kg
Study: 16355944
Drug: saline, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline, 2 mL
Study: 16355944
Drug: ketamine, 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine, 1.2 mg/kg
Study: 9706940
Drug: Topical lidocaine-prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine-prilocaine cream (EMLA)
Study: 7876652
Drug: Inactivated HAV
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated HAV vaccine, 0.5 mL, with second and third doses at 1 and 2 months (Group A)
Study: 7876652
Drug: Inactivated HAV
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated HAV vaccine, 0.5 mL, with second and third doses at 1 and 6 months (Group B)
Study: 2213800
Drug: Dimethicone/antacid (Asilone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethicone/antacid (Asilone Gel)
Study: 2213800
Drug: Alginate/antacid (Gaviscon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate/antacid (Gaviscon liquid)
Study: 28803333
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg TLV
Study: 28803333
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg TLV
Study: 28803333
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg TLV
Study: 24917527
Drug: Psychological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological intervention and oral health education before and after treatment
Study: 24917527
Drug: Regular doctor's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular doctor's advice after treatment (Control)
Study: 21178180
Drug: Crystalline l-Thr
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalline l-Thr added to basal diet (60% of NRC recommendation in Exp. 1 and 20-60% in Exp. 2)
Study: 19414053
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose alcohol (0.2 g/kg)
Study: 19414053
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose alcohol (0.4 g/kg)
Study: 12151972
Drug: Fludarabine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (25 mg/m2 intravenously on days 1-5) followed by interferon-α-2a (2 × 106 U/m2 subcutaneously on days 22-26)
Study: 2726771
Drug: Chimeric monoclonal
Normalized name: Chimeric monoclonal antibody to mesothelin
DrugBank: Amatuximab (DB12845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric monoclonal antibody (mAb) 10 mg single infusion
Study: 2726771
Drug: Chimeric monoclonal
Normalized name: Chimeric monoclonal antibody to mesothelin
DrugBank: Amatuximab (DB12845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric monoclonal antibody (mAb) 40 mg single infusion
Study: 2726771
Drug: Chimeric monoclonal
Normalized name: Chimeric monoclonal antibody to mesothelin
DrugBank: Amatuximab (DB12845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric monoclonal antibody (mAb) 10 mg three infusions
Study: 2726771
Drug: Chimeric monoclonal
Normalized name: Chimeric monoclonal antibody to mesothelin
DrugBank: Amatuximab (DB12845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric monoclonal antibody (mAb) 40 mg three infusions
Study: 29512827
Drug: 170 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 170 mug LPP administered subcutaneously over 3 weeks
Study: 24359543
Drug: Complex intervention
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex intervention for GPs including interactive workshops, audit and feedback reports, automated electronic prompts, and a recommendation for delayed antimicrobial treatment.
Study: 18387160
Drug: Sevelamer (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevelamer (3.0 g/day)
Study: 18387160
Drug: Sevelamer with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevelamer with CaCO3 (3.0 g/day)
Study: 18387160
Drug: Colestimide with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestimide with CaCO3 (3.0 g/day)
Study: 16343856
Drug: Ciprofloxacin XR
Normalized name: ciprofloxacin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin XR 1000 mg
Study: 9391723
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of heparin based on initial patient-specific dose per unit weight and adjustments during CPB based on reference heparin concentration.
Study: 9391723
Drug: Monitoring group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring group using bolus administration of heparin calculated by the Hepcon instrument during CPB.
Study: 9391723
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received similar doses of heparin and protamine, and had similar transfusion requirements.
Study: 7933485
Drug: Intrathecal buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal buprenorphine (0.05 mg)
Study: 7933485
Drug: Intrathecal buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal buprenorphine (0.075 mg)
Study: 3328281
Drug: Sucralfate treatment
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate treatment
Study: 30698458
Drug: Vapocoolant spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapocoolant spray prior to SC heparin injection
Study: 30698458
Drug: Water spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water spray (placebo) prior to SC heparin injection
Study: 22321976
Drug: Non-exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-exercise group (daily activities).
Study: 16922471
Drug: Short-term donepezil
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term donepezil therapy (3 months)
Study: 16922471
Drug: Long-term donepezil
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term donepezil therapy (1 year)
Study: 9222672
Drug: 500 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 U/kg of r‐HuEPO divided in three doses (300 U/kg 12 days before surgery, 100 U/kg 4 and 8 days later)
Study: 9222672
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (r‐HuEPO treatment)
Study: 3616754
Drug: Narcotic analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narcotic analgesic (meperidine hydrochloride) plus antispasmodics (diazepam and baclofen)
Study: 3616754
Drug: Narcotic analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narcotic analgesic (meperidine hydrochloride) alone
Study: 23635616
Drug: Minimal residue
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal residue diet plus mechanical bowel preparation with oral sodium picosulphate
Study: 23635616
Drug: Minimal residue
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal residue diet plus mechanical bowel preparation
Study: 17884341
Drug: Tri E
Normalized name: Evernia prunastri extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri E Tocotrienol 160 mg daily for 6 months
Study: 11203592
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no EDTA gel)
Study: 9337677
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon (IFN)
Study: 8409113
Drug: Aspartame (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (50, 300, 600 mg doses; half doses for subjects weighing less than 40 kg)
Study: 3531314
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g daily for 5 weeks
Study: 25884778
Drug: Diclegis® (doxylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclegis® (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg)
Study: 15175031
Drug: Anti-IL-5 monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-IL-5 monoclonal antibody (mepolizumab)
Study: 11305700
Drug: Nefazodone, average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone, average end‐of‐treatment dose 376 mg/day
Study: 15251769
Drug: 70/30 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70/30 insulin (premixed 30% regular insulin and 70% NPH insulin), administered twice daily for 4 weeks
Study: 15251769
Drug: NPH insulin,
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin, administered twice daily for 4 weeks
Study: 15251769
Drug: 70/30 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70/30 insulin (premixed 30% regular insulin and 70% NPH insulin)
Study: 25853533
Drug: Home visits
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home visits conducted by family medicine residents
Study: 23740935
Drug: Neoadjuvant docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant docetaxel and GVAX therapy
Study: 19665354
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (n=6) - roughened implant surface by sandblasting only
Study: 19665354
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (n=12) - implant surface with additional macroretentions
Study: 11759182
Drug: PDRN (5625
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDRN (5625 mg/vial) administered intramuscularly once daily and subcutaneously (2 vials every 3 days) for 10 days
Study: 11759182
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intramuscularly once daily and subcutaneously (2 vials every 3 days) for 10 days
Study: 3277419
Drug: Indapamide 2.5
Normalized name: indapamide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 2.5 mg once daily